Literature DB >> 31310230

Potential Fifth Clade of Candida auris, Iran, 2018.

Nancy A Chow, Theun de Groot, Hamid Badali, Mahdi Abastabar, Tom M Chiller, Jacques F Meis.   

Abstract

Four major clades of Candida auris have been described, and all infections have clustered in these 4 clades. We identified an isolate representative of a potential fifth clade, separated from the other clades by >200,000 single-nucleotide polymorphisms, in a patient in Iran who had never traveled outside the country.

Entities:  

Keywords:  Candida auris; antimicrobial resistance; clades; clonal; fungal infections; fungi; genotyping; multidrug-resistant infections; typing; whole-genome sequencing

Mesh:

Year:  2019        PMID: 31310230      PMCID: PMC6711235          DOI: 10.3201/eid2509.190686

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


In the past decade, Candida auris has emerged in healthcare facilities as a multidrug-resistant pathogen that can cause outbreaks of invasive infections (). C. auris has now been identified in >35 countries, many of which have documented healthcare-associated person-to-person spread (). Transmission of this yeast is facilitated by its ability to colonize skin and other body sites, as well as its ability to persist for weeks on surfaces and equipment (). Whole-genome sequencing of C. auris has identified 4 major populations in which isolates cluster by geography (). These populations are commonly referred to as the South Asian (I), East Asian (II), African (III), and South American (IV) clades. Worldwide, C. auris isolates continue to cluster in 1 of the 4 clades (Figure; –). We report an isolate representative of a fifth clade in Iran from a patient who never traveled outside that country. The patient was a 14-year-old girl in whom C. auris otomycosis had been diagnosed; her case was the first known C. auris case in Iran ().
Figure

Major clades of Candida auris. Maximum-likelihood phylogenetic tree shows isolates from C. auris cases from 10 countries. Circles at nodes indicate separations with a bootstrap value >99%.

Major clades of Candida auris. Maximum-likelihood phylogenetic tree shows isolates from C. auris cases from 10 countries. Circles at nodes indicate separations with a bootstrap value >99%. We conducted whole-genome sequencing of the isolate from Iran and 74 isolates from other countries (Appendix) and confirmed that the isolate from Iran was genetically distinct from the 4 existing clades, having a difference of >200,000 single-nucleotide polymorphisms compared with the other 4 clades. Isolates from the East Asian clade were its closest neighbors. Within the South Asian clade, isolates from C. auris cases in India, Pakistan, the United Kingdom, and the United States clustered together; within the East Asian clade, isolates from cases in Japan, South Korea, and the United States clustered together; within the African clade, isolates from cases in South Africa, the United Kingdom, and the United States clustered together; and within the South American clade, isolates from cases in Colombia, the United States, and Venezuela clustered together (Figure). The C. auris isolate from Iran appears to represent a fifth major clade. Although this case was reported in 2018, additional cases of C. auris infections and colonization are thought to exist in Iran, given that challenges in diagnostic capacity in the country have probably limited the identification of more C. auris cases. The patient in this case was reported to have never traveled outside Iran (), suggesting that this population structure might not be a result of a recent C. auris introduction into the country and that it might have emerged in Iran some time ago. Determining whether additional C. auris cases exist in Iran and whether such strains are related will help shed light on how C. auris emerged in Iran. The isolate from Iran was susceptible to the 3 major classes of antifungal drugs and was cultured from ear swab specimens from the patient (). C. auris of the East Asian clade is thought to have a propensity for the ear that is uncharacteristic of the other major clades (). A recent study showed that, of 61 C. auris isolates obtained from 13 hospitals across South Korea during a 20-year period, 57 (93%) came from ear cultures (). Although a systematic analysis has not been conducted, there are limited reports of ear infections or colonization caused by C. auris of the South Asian, African, or South American clades, so it is of interest that the isolate from Iran was most closely related to isolates of the East Asian clade, albeit with a difference of hundreds of thousands of single nucleotide polymorphisms. Ultimately, our discovery is a reminder that much about C. auris remains to be learned and underscores the need for vigilance in areas where C. auris has not yet emerged.

Appendix

Additional information regarding a potential fifth clade of Candida auris, Iran, 2018.
  10 in total

1.  Insights into the Unique Nature of the East Asian Clade of the Emerging Pathogenic Yeast Candida auris.

Authors:  Rory M Welsh; D Joseph Sexton; Kaitlin Forsberg; Snigdha Vallabhaneni; Anastasia Litvintseva
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

Review 2.  Candida auris otomycosis in Iran and review of recent literature.

Authors:  Mahdi Abastabar; Iman Haghani; Fatemeh Ahangarkani; Mohammad Sadegh Rezai; Mojtaba Taghizadeh Armaki; Somayeh Roodgari; Keyvan Kiakojuri; Abdullah M S Al-Hatmi; Jacques F Meis; Hamid Badali
Journal:  Mycoses       Date:  2019-02       Impact factor: 4.377

3.  Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses.

Authors:  Shawn R Lockhart; Kizee A Etienne; Snigdha Vallabhaneni; Joveria Farooqi; Anuradha Chowdhary; Nelesh P Govender; Arnaldo Lopes Colombo; Belinda Calvo; Christina A Cuomo; Christopher A Desjardins; Elizabeth L Berkow; Mariana Castanheira; Rindidzani E Magobo; Kauser Jabeen; Rana J Asghar; Jacques F Meis; Brendan Jackson; Tom Chiller; Anastasia P Litvintseva
Journal:  Clin Infect Dis       Date:  2016-10-20       Impact factor: 9.079

Review 4.  Candida auris.

Authors:  Katja Saris; Jacques F Meis; Andreas Voss
Journal:  Curr Opin Infect Dis       Date:  2018-08       Impact factor: 4.915

5.  Molecular Epidemiology of Candida auris in Colombia Reveals a Highly Related, Countrywide Colonization With Regional Patterns in Amphotericin B Resistance.

Authors:  Patricia Escandón; Nancy A Chow; Diego H Caceres; Lalitha Gade; Elizabeth L Berkow; Paige Armstrong; Sandra Rivera; Elizabeth Misas; Carolina Duarte; Heather Moulton-Meissner; Rory M Welsh; Claudia Parra; Luz Angela Pescador; Nohora Villalobos; Soraya Salcedo; Indira Berrio; Carmen Varón; Andrés Espinosa-Bode; Shawn R Lockhart; Brendan R Jackson; Anastasia P Litvintseva; Mauricio Beltran; Tom M Chiller
Journal:  Clin Infect Dis       Date:  2019-01-01       Impact factor: 9.079

6.  Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast Candida auris on a Plastic Health Care Surface.

Authors:  Rory M Welsh; Meghan L Bentz; Alicia Shams; Hollis Houston; Amanda Lyons; Laura J Rose; Anastasia P Litvintseva
Journal:  J Clin Microbiol       Date:  2017-07-26       Impact factor: 5.948

7.  Candida auris Clinical Isolates from South Korea: Identification, Antifungal Susceptibility, and Genotyping.

Authors:  Yong Jun Kwon; Jong Hee Shin; Seung A Byun; Min Ji Choi; Eun Jeong Won; Dain Lee; Seung Yeob Lee; Sejong Chun; Jun Hyung Lee; Hyun Jung Choi; Seung Jung Kee; Soo Hyun Kim; Myung Geun Shin
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

8.  Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: a molecular epidemiological survey.

Authors:  Nancy A Chow; Lalitha Gade; Sharon V Tsay; Kaitlin Forsberg; Jane A Greenko; Karen L Southwick; Patricia M Barrett; Janna L Kerins; Shawn R Lockhart; Tom M Chiller; Anastasia P Litvintseva
Journal:  Lancet Infect Dis       Date:  2018-10-04       Impact factor: 25.071

Review 9.  Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally.

Authors:  Anuradha Chowdhary; Cheshta Sharma; Jacques F Meis
Journal:  PLoS Pathog       Date:  2017-05-18       Impact factor: 6.823

10.  Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris.

Authors:  Johanna Rhodes; Alireza Abdolrasouli; Rhys A Farrer; Christina A Cuomo; David M Aanensen; Darius Armstrong-James; Matthew C Fisher; Silke Schelenz
Journal:  Emerg Microbes Infect       Date:  2018-03-29       Impact factor: 7.163

  10 in total
  94 in total

1.  Categorizing Susceptibility of Clinical Isolates of Candida auris to Amphotericin B, Caspofungin, and Fluconazole by Use of the CLSI M44-A2 Disk Diffusion Method.

Authors:  Natalie S Nunnally; Tajah Damm; Shawn R Lockhart; Elizabeth L Berkow
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

Review 2.  Candida auris: a fungus with identity crisis.

Authors:  Taissa Vila; Ahmed S Sultan; Daniel Montelongo-Jauregui; Mary Ann Jabra-Rizk
Journal:  Pathog Dis       Date:  2020-06-01       Impact factor: 3.166

3.  Molecular Identification and Antifungal Susceptibility of Yeasts and Molds Isolated from Patients with Otomycosis.

Authors:  Keyvan Kiakojuri; Saeid Mahdavi Omran; Somayeh Roodgari; Mojtaba Taghizadeh Armaki; Mohammad Taghi Hedayati; Tahereh Shokohi; Iman Haghani; Javad Javidnia; Firoozeh Kermani; Hamid Badali; Mahdi Abastabar
Journal:  Mycopathologia       Date:  2021-03-15       Impact factor: 2.574

4.  Laboratory Analysis of an Outbreak of Candida auris in New York from 2016 to 2018: Impact and Lessons Learned.

Authors:  YanChun Zhu; Brittany O'Brien; Lynn Leach; Alexandra Clarke; Marian Bates; Eleanor Adams; Belinda Ostrowsky; Monica Quinn; Elizabeth Dufort; Karen Southwick; Richard Erazo; Valerie B Haley; Coralie Bucher; Vishnu Chaturvedi; Ronald J Limberger; Debra Blog; Emily Lutterloh; Sudha Chaturvedi
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

5.  In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism.

Authors:  A L Bidaud; F Botterel; A Chowdhary; E Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

6.  Identification of Antifungal Compounds against Multidrug-Resistant Candida auris Utilizing a High-Throughput Drug-Repurposing Screen.

Authors:  Yu-Shan Cheng; Jose Santinni Roma; Min Shen; Caroline Mota Fernandes; Patricia S Tsang; He Eun Forbes; Helena Boshoff; Cristina Lazzarini; Maurizio Del Poeta; Wei Zheng; Peter R Williamson
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

7.  Human Infections Caused by Clonally Related African Clade (Clade III) Strains of Candida auris in the Greater Houston Region.

Authors:  S Wesley Long; Matthew Ojeda Saavedra; Paul A Christensen; James M Musser; Randall J Olsen
Journal:  J Clin Microbiol       Date:  2020-06-24       Impact factor: 5.948

8.  Inactivation of the multi-drug resistant pathogen Candida auris using ultraviolet germicidal irradiation (UVGI).

Authors:  Angela R Lemons; Tia L McClelland; Stephen B Martin; William G Lindsley; Brett J Green
Journal:  J Hosp Infect       Date:  2020-04-10       Impact factor: 3.926

9.  In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak.

Authors:  YanChun Zhu; Shannon Kilburn; Mili Kapoor; Sudha Chaturvedi; Karen Joy Shaw; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

10.  A Selective Medium for Isolation and Detection of Candida auris, an Emerging Pathogen.

Authors:  Sourav Das; Shreya Singh; Yamini Tawde; Arunaloke Chakrabarti; Shivaprakash M Rudramurthy; Harsimran Kaur; Shamanth A Shankarnarayan; Anup Ghosh
Journal:  J Clin Microbiol       Date:  2021-01-21       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.